cPass Neutralization Antibody Detection kit detects circulating neutralizing antibodies against SARS-CoV-2 that block the interaction between the receptor binding domain (RBD) of the viral spike glycoprotein with the ACE2 cell surface receptor. The cPass test is now authorized for semi-quantitative detection that provides a relative concentration result of an adaptive immune response to recent SARS-CoV-2 infection.
Watch the cPass video to learn how it works
Customers should be aware that they may receive product with original packaging prior to the Dec 16, 2021 FDA EUA approval. Such packaging retains the original 6 month expiration. The current inventory is qualified for the extension to 9 months. Should you have questions about your order’s expiration, do not hesitate to contact us to provide updated information related to your order.
A02087 SARS-CoV-2 Neutralizing Antibody Calibrator is now FDA authorized under Emergency Use Authorization with cPass SARS-CoV-2 Neutralization Antibody Detection Kit for semi-quantitative results. New
Safe & Scalable
Featured Video | Learn about COVID-19 and the importance of serology investigation in viral disease outbreak.
Dr. Linfa Wang, Ph.D., FTSE, is the director of the Program in Emerging Infectious Diseases at Duke-NUS Medical School in Singapore. His team at Duke-NUS, worked together with Diagnostics Development Hub and GenScript co-developed cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit.